TFEB Rearranged Renal Cell Carcinoma: Pathological and Molecular Characterization of 10 Cases, with Novel Clinical Implications: A Single Center 10-Year Experience.

Wang, Ai-Xiang; Tian, Tai; Liu, Li-Bo; Yang, Feng; He, Hui-Ying; Zhou, Li-Qun

Wang, Ai-Xiang; Tian, Tai; Liu, Li-Bo; Yang, Feng; He, Hui-Ying; Zhou, Li-Qun.

Afiliação

Wang AX; Department of Urology, National Urological Cancer Center, Peking University First Hospital, Institute of Urology, Peking University, Beijing 100034, China.
Tian T; Department of Urology, National Urological Cancer Center, Peking University First Hospital, Institute of Urology, Peking University, Beijing 100034, China.
Liu LB; Department of Urology, National Urological Cancer Center, Peking University First Hospital, Institute of Urology, Peking University, Beijing 100034, China.
Yang F; Department of Urology, National Urological Cancer Center, Peking University First Hospital, Institute of Urology, Peking University, Beijing 100034, China.
He HY; Department of Pathology, School of Basic Medical Sciences, Third Hospital, Peking University Health Science Center, Beijing 100191, China.
Zhou LQ; Department of Urology, National Urological Cancer Center, Peking University First Hospital, Institute of Urology, Peking University, Beijing 100034, China.

Biomedicines ; 11(2)2023 Jan 18.

Article em En | MEDLINE | ID: mdl-36830782

Palavras-chave

PD-L1; TFEB rearranged RCC; differential diagnosis; immunohistochemistry; immunotherapy; the incidence rate

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Biomedicines Ano de publicação: 2023 Tipo de documento: Article País de afiliação: China

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google